Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology
Puma Inc 2024 | www.favors.com
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology Surging
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
Puma Biotechnology falls more than 20%
Puma Biotechnology unveils Phase II breast cancer trial design
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology, Inc. | CDISC
Puma Biotechnology
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotech's Stock Soars to New High, but Technical Analysis Signals Caution
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
